Premier (PINC) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Jul, 2026Executive summary
Revenue and profitability for the first half of fiscal 2025 met expectations, with Supply Chain Services outperforming and Performance Services underperforming; net revenue for Q2 FY2025 was $240.3M, down 14% year-over-year.
Adjusted EBITDA for the quarter was $50.1M (20.8% margin), down 48% year-over-year; adjusted EPS was $0.25 ($0.27 excluding Contigo Health).
GAAP net loss from continuing operations was $45.8M, mainly due to a $126.8M goodwill impairment in Performance Services.
The company completed the sale of S2S Global and the network assets of Contigo Health, with further divestitures planned.
Share repurchases exceeded 29M shares for $600M, with $200M repurchased in early January 2025; $0.21 per share dividend declared for March.
Financial highlights
Net revenue for Q2 FY2025 was $240.3M, down 14% year-over-year, driven by declines in both Supply Chain Services and Performance Services.
Adjusted EBITDA was $50.1M, and adjusted EPS was $0.25, both down sharply year-over-year.
Free cash flow for the first half was $73.9M, up $33M year-over-year, aided by a lawsuit settlement and minority investment distribution.
Cash and cash equivalents at quarter-end were $85.9M; $100M outstanding on the $1B credit facility, with $65M repaid in January.
Operating expenses rose 75% to $264.0M, mainly due to the goodwill impairment.
Outlook and guidance
Fiscal 2025 total net revenue guidance (excluding Contigo Health): $940M–$1.01B, midpoint reaffirmed.
Adjusted EBITDA guidance: $237M–$253M; adjusted EPS guidance raised to $1.26–$1.34, reflecting share repurchases.
Net administrative fees revenue guidance increased to $525M–$545M.
Capital expenditures expected at $90M–$100M; effective tax rate 24%–26%.
GPO business expected to have flat to slightly higher net administrative fees in Q3, with a sequential increase in Q4.
Latest events from Premier
- Leadership changes and tech innovation drive growth, efficiency, and strong capital returns.PINC
43rd Annual J.P. Morgan Healthcare Conference 20259 Jul 2026 - Q1 net income rose 75% on a $57M legal gain, despite an 8% revenue decline.PINC
Q1 20258 Jul 2026 - Q4 revenue up 3%, FY25 guidance targets $1.02B revenue, $1.28 EPS, excluding divestitures.PINC
Q4 202423 Jan 2026 - AI-driven supply chain and shared services are key to transformative savings and future growth.PINC
Leerink’s Global Healthcare Conference 202518 Dec 2025 - Definitive merger agreement for $28.25/share cash buyout, board-approved, pending shareholder vote.PINC
Proxy Filing1 Dec 2025 - Shareholders to vote on $28.25 per share all-cash merger, board unanimously recommends approval.PINC
Proxy Filing1 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong ESG focus.PINC
Proxy Filing1 Dec 2025 - Shareholders to vote on a $28.25 per share all-cash merger, unanimously backed by the board.PINC
Proxy Filing1 Dec 2025 - Acquisition by Patient Square Capital will take the company private, pending approvals.PINC
Proxy Filing1 Dec 2025